BeOne Medicines’ Tevimbra combination extends median survival to 27 months in gastroesophageal cancer trial
ONC•BeOne Medicines said its Tevimbra combination extended median survival to 27 months in a first-line trial for advanced HER2-positive gastroesophageal adenocarcinoma. The benefit over Ziihera with chemotherapy alone did not reach statistical significance.
1. Trial results
BeOne Medicines reported sustained survival benefits for Tevimbra with Ziihera and chemotherapy in the Phase 3 HERIZON-GEA-01 trial. Patients lived longer than those receiving trastuzumab-based chemotherapy, but the benefit over Ziihera with chemotherapy alone did not reach statistical significance. No new safety signals emerged; results are scheduled for presentation at the European Society for Medical Oncology Congress in Madrid.
